Genentech, a member of the Roche Group , announced today that the randomized Phase III CLL14 study, which evaluated fixed-duration Venclexta® in combination with Gazyva® in people with previously untreated chronic lymphocytic leukemia and co-existing medical conditions, met its primary endpoint and showed a statistically significant reduction in the risk of disease worsening or death compared to standard-of-care Gazyva plus chlorambucil.
Source link
Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint
-Medtech_THAI_STUDIO_LAB_249_5668a625a9ad46978c78f22fdb7af040-620x480.jpg)
